Cellebrite DI (NASDAQ:CLBT) Hits New 52-Week High at $17.80

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) hit a new 52-week high during trading on Thursday . The company traded as high as $17.80 and last traded at $17.70, with a volume of 18136 shares trading hands. The stock had previously closed at $17.25.

Analysts Set New Price Targets

A number of analysts recently weighed in on CLBT shares. Needham & Company LLC increased their price target on shares of Cellebrite DI from $14.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Craig Hallum lifted their target price on Cellebrite DI from $16.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, August 16th. JPMorgan Chase & Co. increased their price target on Cellebrite DI from $14.00 to $15.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Deutsche Bank Aktiengesellschaft lifted their price objective on Cellebrite DI from $15.00 to $18.00 and gave the company a “buy” rating in a report on Friday, August 16th. Finally, Bank of America increased their target price on Cellebrite DI from $13.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $17.33.

Cellebrite DI Trading Down 0.2 %

The company has a 50 day simple moving average of $15.15 and a 200 day simple moving average of $12.67. The stock has a market cap of $3.58 billion, a P/E ratio of -30.00, a PEG ratio of 2.41 and a beta of 1.52.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings results on Thursday, August 15th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.02. Cellebrite DI had a negative net margin of 28.51% and a positive return on equity of 5,902.06%. The firm had revenue of $95.70 million for the quarter, compared to analyst estimates of $91.94 million. During the same period in the previous year, the business earned $0.05 EPS. The company’s revenue was up 24.8% compared to the same quarter last year. As a group, sell-side analysts expect that Cellebrite DI Ltd. will post 0.31 earnings per share for the current year.

Institutional Trading of Cellebrite DI

Institutional investors and hedge funds have recently bought and sold shares of the stock. Parallel Advisors LLC increased its holdings in Cellebrite DI by 75.0% during the fourth quarter. Parallel Advisors LLC now owns 3,500 shares of the company’s stock worth $30,000 after buying an additional 1,500 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. raised its stake in Cellebrite DI by 59.6% in the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock valued at $33,000 after buying an additional 1,017 shares during the period. Quarry LP acquired a new stake in shares of Cellebrite DI in the fourth quarter valued at approximately $36,000. Public Employees Retirement Association of Colorado bought a new position in shares of Cellebrite DI during the 2nd quarter worth approximately $71,000. Finally, nVerses Capital LLC acquired a new position in shares of Cellebrite DI in the second quarter valued at $103,000. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.